Tech Company Financing Transactions

Nacuity Pharmaceuticals Funding Round

Foundation Fighting Blindness, Retinal Degeneration and Maxim Group joined a $16.5 million Series B venture round for Nacuity Pharmaceuticals. This venture round was announced by the company on 6/15/2022.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

306 W. 7th St, 310
Fort Worth, TX 76102
USA

Phone

(817) 336-3000

Website

www.nacuity.com

Email Address

[email protected]

Overview

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company's powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has several highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis. The company is pursuing near-term proof-of-concept data in all three programs.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Halden Conner

        

Chief Financial Officer

Charles Lieser

        

Chief Scientific Officer

G. Michael Wall

        

Browse more venture capital transactions:

Prev: 6/15/2022: Rayon venture capital transaction
Next: 6/15/2022: Green Badger venture capital transaction

Share this article

About Our VC Transactions Data

We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary